ClinicalTrials.gg
Not yet recruitingNCT07868224Updated Oct 9, 2026

Validating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials

An interventional study of Sensitization Acupuncture and Traditional Acupuncture in Knee Osteoarthritis; Insomnia; Cervical Spondylosis; Chronic Low Back Pain; Allergic Rhinitis, sponsored by Jiangxi University of Traditional Chinese Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Jiangxi University of Traditional Chinese Medicine · Not applicable, Interventional, and Other

Updated Oct 9, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is the clinical validation component of a broader research program developing a randomized controlled trial (RCT) comparing sensitization acupuncture (an individualized technique in which treatment points are selected by palpation for sensitized acupoints) with traditional acupuncture (a technique using preset, fixed acupoints). To keep participants unaware of which treatment they receive, the program constructed a control design using a structured five-step framework (Deconstruct-Identify-Take out-Think-Optimize, DITTO), in which each treatment incorporates a double-simulation: in sensitization acupuncture, sensitized acupoints are needled genuinely while the preset traditional acupoints receive shallow or non-penetrating needling; in traditional acupuncture, the preset acupoints are needled genuinely while the identified sensitized acupoints receive shallow or non-penetrating needling. This study validates whether this design maintains participant blinding in practice. Thirty participants with one of five conditions (knee osteoarthritis, insomnia, cervical spondylosis, chronic low back pain, or allergic rhinitis) will each receive 10 sessions in a randomized order: 5 sessions of sensitization acupuncture and 5 sessions of traditional acupuncture. After each session, participants will guess which treatment they received, state their reasons, and rate their confidence; blinding will be evaluated using James' and Bang's Blinding Indices. Sensory experience (deqi, pain, needle-penetration perception) and adverse events will also be compared between the two treatments. Results will guide refinement of the control design before its use in the definitive RCT.

Read the detailed description

The sham-sensitization control design validated in this study is one component of a larger research program to develop a randomized controlled trial comparing sensitization acupuncture with traditional acupuncture. The control design was developed through a five-step process based on the DITTO framework, originally proposed by the UK National Institute for Health Research (NIHR) for surgical placebo interventions:

  1. Deconstruct: a systematic literature review identified all procedural elements of sensitization acupuncture, catalogued across pre-treatment, intra-treatment, and post-treatment stages.
  2. Identify: semi-structured interviews with five acupuncture experts and five patient representatives identified 25 key elements whose between-group differences could plausibly cause unblinding or contribute to therapeutic effect.
  3. Take out: for each of the 25 key elements, the corresponding operation was first fully replicated from the sensitization acupuncture group into the traditional acupuncture group to eliminate procedural differences between groups. Each replicated element was then evaluated for potential additional therapeutic effect in the traditional acupuncture group. For the 4 elements judged relevant to therapeutic effect, a dedicated take-out plan was developed to remove or minimize effect-producing content while preserving blinding, and a bidirectional double-simulation was applied: in sensitization acupuncture, the preset traditional acupoints receive shallow or non-penetrating needling; in traditional acupuncture, the identified sensitized acupoints receive shallow or non-penetrating needling. Points receiving simulated needling are located 10-20 mm lateral to the corresponding genuine acupoint to remove therapeutic effect. The remaining 21 elements, judged unrelated to therapeutic effect, were fully replicated (simulated) without further modification.
  4. Think: an expert panel is evaluating the preliminary plan. The 4 elements requiring a take-out plan and double-simulation are being rated on four dimensions:blinding maintenance, residual therapeutic effect, risk of bias, and feasibility. The remaining 21 fully-simulated elements are being rated on three dimensions:therapeutic inertia (absence of a meaningful residual effect), risk of bias, and feasibility, since full simulation between groups is considered to inherently preserve blinding. Results will be used to finalize the draft technical guideline.
  5. Optimize (the present study):Three or five physicians experienced in sensitization acupuncture will pilot-test the draft guideline in 30 participants using a randomized crossover design (5 sensitization acupuncture and 5 traditional acupuncture sessions per participant, sequence generated by permuted block randomization). After each session, participants guess which treatment they received, state their reasons, and rate their confidence (0-10); James' and Bang's Blinding Indices are calculated from these guesses pooled by treatment type, and indices from the 1st versus the 10th session are compared as a pre-specified exploratory analysis. Deqi, pain, and needle-penetration perception ratings and adverse events are compared between the two treatments. Findings will inform refinement of the technical guideline before its use in the definitive RCT.
02

Conditions studied

  • Knee Osteoarthritis; Insomnia; Cervical Spondylosis; Chronic Low Back Pain; Allergic Rhinitis

Keywords

  • acupoint sensitization; sensitization acupuncture; traditional acupuncture; double simulation; blinding; DITTO framework
03

In context

Osteoarthritis, Knee

3,391 studies on the registry are indexed under Osteoarthritis, Knee; 628 are open to participants now.

This study's planned enrollment of 30 is below the median of 69 across 2,808 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Jiangxi University of Traditional Chinese Medicine is the lead sponsor of 15 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-75 years;
  • Clinically diagnosed with one of the following five conditions: knee osteoarthritis, insomnia, cervical spondylosis, chronic low back pain, or allergic rhinitis
  • Presence of palpable sensitized acupoints
  • Willing to receive sensitization acupuncture treatment
  • Able to understand and communicate sufficiently to complete blinding-assessment questionnaires
  • Willing to participate and provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Serious comorbid conditions unrelated to the target disease that could confound assessment (e.g., severe organ failure, malignancy);
  • Concurrent use of other acupoint-stimulation therapies (e.g., moxibustion, tuina, acupoint injection) whose effects cannot be separated from those of sensitization acupuncture
  • Severe coagulation disorder or local skin infection constituting a contraindication to acupuncture
  • Bleeding disorder or current anticoagulant therapy
  • Pregnant or breastfeeding women
  • Severe fear of needles precluding completion of the standard treatment course
  • Cognitive or communication impairment precluding reliable self-report
  • Currently participating in another sensitization-acupuncture-related clinical trial
  • Unwilling to provide informed consent
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Sensitization Acupuncture

    All participants receive this treatment in 5 of their 10 total sessions, interspersed in an individually randomized order with the traditional acupuncture treatment (crossover design).

    Procedure: Sensitization Acupuncture

  • Active comparator
    Traditional Acupuncture

    All participants receive this treatment in 5 of their 10 total sessions, interspersed in an individually randomized order with the sensitization acupuncture treatment (crossover design).

    Procedure: Traditional Acupuncture

Interventions

  • ProcedureSensitization Acupuncture

    Genuine needling (needle insertion, deqi elicitation, and reinforcing-reducing manipulation) at sensitized acupoints identified by palpation. As a double-simulation, the preset traditional acupoints receive shallow or non-penetrating needling at points 10-20 mm lateral to the genuine acupoint, without deqi or manipulation.

  • ProcedureTraditional Acupuncture

    Genuine needling (needle insertion, deqi elicitation, and reinforcing-reducing manipulation) at preset fixed acupoints. As a double-simulation, the sensitized acupoints identified by palpation receive shallow or non-penetrating needling at points 10-20 mm lateral to the genuine acupoint, without deqi or manipulation.

06

What researchers measure

Primary outcomes

  1. James' Blinding Index

    Assessments are conducted after each treatment session, up to Session 10 (scheduled as 2 sessions per week for a total duration of up to 5 weeks). The index is calculated from participants' session-by-session guesses of treatment allocation, pooled across all 10 sessions per participant; reflects overall success of blinding across the trial (range 0-1; 1 indicates perfect blinding, 0.5 indicates guessing consistent with chance). The index computed from the 1st versus the 10th (final) session will additionally be compared as a pre-specified exploratory analysis of whether blinding is maintained as the treatment course progresses.

    Time frame: up to 5 weeks

  2. Bang's Blinding Index

    Assessments are conducted after each treatment session, up to Session 10 (scheduled as 2 sessions per week for a total duration of up to 5 weeks). The index is calculated separately for the sensitization-acupuncture arm and the traditional-acupuncture arm from participants' pooled session-by-session guesses; reflects the direction and magnitude of unblinding within each arm (range -1 to 1; 0 indicates blinding consistent with random guessing). The index is compared between the 1st and 10th sessions as a pre-specified exploratory analysis.

    Time frame: up to 5 weeks

Secondary outcomes

  1. Participant's Confidence in Guessed Treatment Allocation

    Assessments are conducted after each treatment session, up to Session 10 (scheduled as 2 sessions per week for a total duration of up to 5 weeks).Measured using a 0-10 Numeric Rating Scale (NRS), where 0 indicates the participant's guess was a complete guess with no confidence and 10 indicates the participant was completely certain of the guess. Higher scores indicate greater confidence in the stated guess; this is not a clinical outcome and does not represent a 'better' or 'worse' result.

    Time frame: up to 5 weeks

Other outcomes

  1. Acupoint-Specific Deqi Sensation Intensity

    Assessments are conducted after each treatment session, up to Session 10 (scheduled as 2 sessions per week for a total duration of up to 5 weeks). Intensity is measured separately for each of the 10 stimulated acupoints per session (5 sensitization points and 5 traditional points) using the Numeric Rating Scale (NRS). The minimum value is 0 (no sensation at all), and the maximum value is 10 (strongest sensation imaginable). Higher scores indicate a more intense sensation (not applicable as a clinically better or worse outcome). Scores from true needling points and sham needling points will be aggregated and compared.

    Time frame: up to 5 weeks

  2. Acupoint-Specific Needling Pain Intensity

    Assessments are conducted after each treatment session, up to Session 10 (scheduled as 2 sessions per week for a total duration of up to 5 weeks). Pain intensity is measured separately for each of the 10 stimulated acupoints per session (5 sensitization points and 5 traditional points) using the Numeric Rating Scale (NRS). The minimum value is 0 (no pain at all), and the maximum value is 10 (most severe pain imaginable). Higher scores mean a worse outcome. Scores from true needling points and sham needling points will be aggregated and compared.

    Time frame: up to 5 weeks

  3. Acupoint-Specific Needle-Penetration Perception Intensity

    Assessments are conducted after each treatment session, up to Session 10 (scheduled as 2 sessions per week for a total duration of up to 5 weeks). Penetration perception is measured separately for each of the 10 stimulated acupoints per session (5 sensitization points and 5 traditional points) using the Numeric Rating Scale (NRS). The minimum value is 0 (no perceived penetration at all), and the maximum value is 10 (deepest perceived penetration). Higher scores indicate a more intense perceived sensation (not applicable as a clinically better or worse outcome). Scores from true needling points and sham needling points will be aggregated and compared.

    Time frame: up to 5 weeks

  4. Incidence and Severity of Adverse Events

    Assessments are conducted after each treatment session, up to Session 10 (scheduled as 2 sessions per week for a total duration of up to 5 weeks).Adverse events will be recorded after every session and compared between sensitization acupuncture and traditional acupuncture by incidence and severity (mild/moderate/severe).

    Time frame: up to 5 weeks

07

Study locations

1 site
  • Jiangxi University of Chinese Medicine
    Nanchang, Jiangxi 330000, China
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data will not be shared. Given the small pilot sample size (n=30), de-identified data may still carry a risk of re-identification. In addition, the study team has not established a formal data-sharing infrastructure or repository at this stage.

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07868224
Lead sponsor
Jiangxi University of Traditional Chinese Medicine
Collaborators
The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
Responsible party
Xu Zhou (Professor, Jiangxi University of Traditional Chinese Medicine) — Principal investigator
First posted
Oct 9, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 9, 2026

Study contacts

Xu Zhou, PhD
Contact
zhouxu_ebm@hotmail.com
18870050733

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion